Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DB-1310 by Duality Biologics (Shanghai) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....